StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
3671.T$302.00-2.27%
Fair $302.00+0.0%

3671.T

Softmax Co., Ltd

Healthcare / Health Information ServicesTokyo

$302.00

-7.00 (-2.27%)

Fairly Valued+0.0%Fair Value $302.00Fund rank 33/100 · Data gapFallback financials|
SA 55/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $359.3M · quality 62.7/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 60/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

55/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 3671.TLocal privado en este navegador · Softmax Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7.3B

P/E

12.7x

↓

EV/EBITDA

7.8x

↓

ROE

14.6%

↑

Gross Margin

26.9%

↓

Debt/Equity

0.63

↑
52-Week Range$302
$222$442

TradingView lightweight chart

3671.T price, volumen y niveles de valoración

Último $302.00Periodo -24.5%
Fair value: $302.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+11.1%

FCF CAGR

+29.9%

FCF margin

5.2%

FCF / Net income

0.63x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $6.93B · net income $573.5M · FCF $359.3M

2022-FY → 2025-FY

Gross margin

26.9%-1.7% pts

Operating margin

10.7%-0.2% pts

Net margin

8.3%-0.0% pts

FCF margin

5.2%+1.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$6.93B$6.93B$5.43B$5.26B$5.05B
Net Income$573.5M$573.5M$480.2M$452.8M$419.4M
EBITDA$849.9M$849.9M$745.4M$659.7M$624.1M
EPS23.8723.8720.0118.8817.54
Gross Margin26.9%26.9%30.8%29.8%28.6%
Operating Margin10.7%10.7%12.2%11.0%10.8%
Net Margin8.3%8.3%8.8%8.6%8.3%
Balance Sheet
Debt/Equity0.630.630.400.410.46
Current Ratio1.551.55———
Cash Flow
Free Cash Flow$359.3M$359.3M$622.9M$206.8M$163.8M
Returns
ROE14.6%14.6%13.6%14.1%14.3%
Valuation
P/E12.6612.6610.439.9412.33
EV/EBITDA7.797.793.984.425.89
P/B1.851.851.421.401.76
Growth & Yield
Revenue Growth27.6%27.6%3.2%4.2%—
EPS Growth19.3%19.3%6.0%7.7%—
Dividend Yield3.3%3.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

3.9%

fácil

EPS terminal req.

$26.80

Spread vs growth

15.4%

5Y implied EPS CAGR

6.3%

razonable

EPS terminal req.

$32.42

Spread vs growth

13.0%

10Y implied EPS CAGR

8.1%

razonable

EPS terminal req.

$52.22

Spread vs growth

11.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +38.1%

Total return

+38.1%

Start / end P/E

11.2x → 12.7x

EPS bridge

20.01 → 23.87

Residual

+2.5%

EPS growth+19.3%
Multiple rerating+13.0%
Dividend+3.3%
Residual / FX / buybacks / cross-term+2.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.